TALVEY ® (talquetamab-tgvs) and DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma
Updated data show 100 percent overall response rate with 56 percent of patients achieving complete response or better with weekly dosing, supporting the combinability of the GPRC5D bispecific antibody
Safety profile, including infection rates,...
Zur Pressemeldung auf www.jnj.com